Alerta De Seguridad para Extensions DBS - Deep Brain Stimulation System. Anvisa Registry n ° 10339190320. Models under risk: 37085 and 37086.

Según Agência Nacional de Vigilância Sanitária (ANVISA), este evento ( alerta de seguridad ) involucró a un dispositivo médico en Brazil que fue producido por Medtronic Comercial Ltda.; Medtronic Puerto Rico operations Co. MPRI.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • ID del evento
    1575
  • Fecha
    2015-05-12
  • País del evento
  • Fuente del evento
    ANVISA
  • URL de la fuente del evento
  • Notas / Alertas
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Notas adicionales en la data
    Medtronic has completed the review of fourteen (14) extensions between October 1, 2014 and March 2, 2015 for high impedance complaints. According to client reports, the high impedance for thirteen (13) of the extensions was observed in the implant and one extension after approximately two months of implantation. Medtronic's analysis of returned extensions identified conductor wire fractures near the location where the extension exits the connector block and not within the connector block itself. In all fourteen (14) cases (occurrence rate of 0.14%), extension was reported to have been successfully replaced, but resulted in a prolonged surgical procedure for thirteen (13) cases and one revision surgery for one approximately two months from the implant. The investigation of Medtronic's root cause of this problem is under way. A damaged extension not detected during the implant procedure could result in loss of stimulation.
  • Causa
    Possibility of fractures occurring in the conductor wire, near the location where the extension exits the connector block.
  • Acción
    The company is sending out Urgent Safety Notice letters to the customers involved in order to reinforce information on the handling of the product in question already on the product label. The current label for system handling during implantation is described within the implant manual, distributed with each device. To minimize the potential of a driver's wire fracture, you should follow the instructions in the Neurostimulator implant manual regarding the extension implant to specifically ensure that the extension does not bend too much or bend. For more detailed information, refer to the Safety Notice issued by the company at: http://portal.anvisa.gov.br/wps/connect/c6b5c9804859842faa60ab734e60b39c/FA648+-+Professional++++++++++++++++++++++++++++++++ BAde.pdf? MOD = AJPERES

Manufacturer

  • Empresa matriz del fabricante (2017)
  • Comentario del fabricante
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    ANVSANVISA